Elios Therapeutics Phase IIb Personalized Vaccine Study Yields Positive Top-Line Results

Jul 18, 2019

|

NEW YORK – Elios Therapeutics reported positive top-line results from a Phase IIb study involving its personalized vaccine in patients with advanced, resected melanoma.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Elios Therapeutics Phase IIb Personalized Vaccine Study Yields Positive Top-Line Results

To read the full story....

Breaking News

NOTCH Mutations Potentially Predictive for Immunotherapy Response in Lung Cancer

Breast Cancer Subtypes Vary With Indigenous Ancestry in Latin American Women

VBL Therapeutics, NanoCarrier to Expand Clinical Trial of Ovarian Cancer Drug to Japan

BeiGene, Zymeworks Dose First Patient in Phase IB/II Trial for HER2-Positive Cancers

Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows

Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

Featured White Papers

What's Popular?

Breast Cancer Subtypes Vary With Indigenous Ancestry in Latin American Women

Adventist Health, CancerIQ Collaboration Identifying More Patients for Guidelines-Supported Genetic Testing

Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

NOTCH Mutations Potentially Predictive for Immunotherapy Response in Lung Cancer

Metastatic Prostate Cancer Features Linked to Immunotherapy Response, Despite Low TMB

Sponsorships